Navigation Links
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Date:6/25/2008

TSX Venture: QPT

EDMONTON, June 25 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company"), today announced interim results from its Phase I/II clinical study designed to investigate appropriate treatment parameters for the potential use of its proprietary compound SL017 for hair removal applications. The interim results represent data from the first 80 patients enrolled in the targeted 100-patient clinical trial.

"The Phase I/II interim results demonstrated that SL017 is safe and well tolerated when used either alone or in combination with photo activation," said Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along with results from the previous clinical trial, support the utility of SL017 for hair removal applications, especially for those who do not benefit from light treatment alone."

To permanently remove unwanted hair, existing laser hair removal techniques require four to eight treatments, and provide only a 75 to 85 percent permanent hair reduction in a limited patient population. The professional laser hair removal market is estimated to be $5 billion worldwide.

Quest is developing SL017 photodynamic therapy (PDT) as a potential hair removal solution that is effective across a broad patient population including those with light colored hair (for example, grey or blonde hair). In a Phase I clinical trial, Quest demonstrated the preferential localization of SL017 in hair follicles, which suggested that cutaneous PDT with SL017 has potential for permanent hair removal applications.

The Phase I/II trial of SL017 was designed to evaluate the effect of skin treatment on follicular uptake of SL017, assess the tolerable light dose on healthy subjects, and subsequently, determine the efficacy of hair removal under optimal treatment conditions. Results from this study will be used to guide the design of future clinical development.

Skin Pret
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Focus on Pharma & Life Science, Gerresheimer AG ... business segment, which primarily manufactures system,components for suppliers to ... of pharma & life science. For this purpose the ... bids., "Through the sale of the technical plastics ...
... -, BRISBANE, Calif., July 31 InterMune, Inc.,(Nasdaq: ... and six months ended June 30, 2008. InterMune reported a ... or $0.68 per share,compared with a net loss of $19.8 ... Dan Welch, Chairman, Chief Executive Officer and President of ...
... ANGELES, July 31 Vista Partners announced today,that ... "Raptor,s drug,candidates, which target billion dollar markets, are ... Company will present Phase 2 results for,Convivia(TM) sometime ... expect FDA approval,of Delayed Release (DR) Cysteamine for ...
Cached Biology Technology:Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics 2InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2008 Financial Results and Business Highlights 10Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is insourcing its ... counterfeit microcircuits from entering into its supply chain. ... anti-counterfeit initiative dubbed DNA marking. The capability will validate ... throughout the supply chain. The new quality control measures ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... played out 73 million years ago in northwestern Alberta ... species in northwestern Alberta. University of Alberta student ... from Italy, made the discovery near Grande Prairie, 450 ... came across a nesting site and found the remains ...
... release is available in German . ... of the limited amount of fossil fuels available, renewable ... other plant waste, are becoming the focus of considerable ... conversion of biomass into bio-oil, a highly promising renewable ...
... 2009) The National Oceanic and Atmospheric Administration ... of a new cooperative institute which will be ... Florida Atlantic University in Fort Pierce, Florida, and ... (UNCW). This is the single largest competitive research ...
Cached Biology News:New dinosaur species possible in Northwestern Alberta 2Biomass as a source of raw materials 2NOAA awards $22.5 million to Harbor Branch/FAU and UNCW for new cooperative institute 2NOAA awards $22.5 million to Harbor Branch/FAU and UNCW for new cooperative institute 3
... new HydroFlex platform provides excellent performance, ... of 96-well format applications, including washing ... arrays, and vacuum filtration-to-waste, such as ... on-line control features set new standards ...
... Obtain Clean and Accurate Results Laser ... increase the sensitivity and accuracy of molecular ... cell types and multi-cellular structures isolated from ... approach to microdissection-developed in 1996 at the ...
... raised against a partial recombinant ... ZFHX4 (NP_078997, 2 a.a. ... protein with GST tag. ... NM_024721 Protein ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Biology Products: